Patents by Inventor Pei Zhou

Pei Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9908851
    Abstract: Disclosed are compounds of formulae: (I) and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, Y, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: March 6, 2018
    Assignees: Duke University, University of North Carolina Chapel Hill
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas
  • Publication number: 20170349544
    Abstract: Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Application
    Filed: August 21, 2017
    Publication date: December 7, 2017
    Inventors: Pei Zhou, Eric J. Toone
  • Patent number: 9738604
    Abstract: Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: August 22, 2017
    Assignee: Duke University
    Inventors: Pei Zhou, Eric J. Toone
  • Publication number: 20160221934
    Abstract: Disclosed are compounds of formulae: (I), and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R21, R22, R23, R34, R37, R33, R39, D, Q, Y, X, X1, X3, and X4 are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Application
    Filed: August 18, 2014
    Publication date: August 4, 2016
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas
  • Publication number: 20160200673
    Abstract: Disclosed are compounds of formulae (I) and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, Y, Z, X, R12, R17, R18, R19, Y1, Z1, X1, and X2 are defined herein. These compounds are useful for treating Gram-negative bacteria infections, such as Neisseria gonorrhoeae bacterial infections.
    Type: Application
    Filed: August 18, 2014
    Publication date: July 14, 2016
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas
  • Publication number: 20160200682
    Abstract: Disclosed are compounds of formulae: (I) and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, Y, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Application
    Filed: August 18, 2014
    Publication date: July 14, 2016
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas
  • Publication number: 20130231323
    Abstract: Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Application
    Filed: September 6, 2011
    Publication date: September 5, 2013
    Applicant: DUKE UNIVERSITY
    Inventors: Pei Zhou, Eric J. Toone
  • Publication number: 20120020991
    Abstract: The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity.
    Type: Application
    Filed: October 7, 2011
    Publication date: January 26, 2012
    Applicant: BioZyme, Inc.
    Inventors: Marcia Moss, Pei Zhou
  • Patent number: 8034783
    Abstract: The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: October 11, 2011
    Assignees: Biozyme, Inc., Duke University
    Inventors: Marcia Moss, Pei Zhou
  • Publication number: 20100081620
    Abstract: The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity.
    Type: Application
    Filed: October 16, 2009
    Publication date: April 1, 2010
    Inventors: Marcia Moss, Pei Zhou
  • Patent number: 7638301
    Abstract: The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: December 29, 2009
    Assignees: BioZyme, Inc., Duke University
    Inventors: Marcia Moss, Pei Zhou
  • Publication number: 20090281049
    Abstract: Use of ginsenoside Compound-K, which structural formula is the following: in manufacturing medicaments for prevention or treatment of arthritis.
    Type: Application
    Filed: August 6, 2007
    Publication date: November 12, 2009
    Inventors: Quanhai Liu, Pei Zhou, Hua Bai, Wei Zhou, Jingjing Li, Meiqing Feng, Moli Hua, Jingyue Xu
  • Publication number: 20080096820
    Abstract: The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity.
    Type: Application
    Filed: August 28, 2007
    Publication date: April 24, 2008
    Inventors: Marcia Moss, Pei Zhou
  • Publication number: 20030092885
    Abstract: The present invention provides methods of stabilizing proteins in solution. More particularly, the present invention provides a method of solublizing and stabilizing a target protein in solution by forming a fusion protein of the target protein with a small solubility and stability enhancing tag. The present invention also features methods of determining the structure of a target protein using a fusion protein to stabilize the target protein in solution.
    Type: Application
    Filed: July 31, 2002
    Publication date: May 15, 2003
    Applicant: President and Fellows of Harvard College
    Inventors: Pei Zhou, Alexey Lugovskoy, Gerhard Wagner
  • Patent number: 5906483
    Abstract: An apparatus for drying/calcining comprises a horizontally extending rotatable drum and a center tube, concentrically positioned within the rotatable drum to provide an annular combustion chamber between the outer wall of the center tube and the inner wall of the rotatable drum. One or more gas jet burners are positioned to inject gas fuel and combustion air into the annular combustion chamber in a tangential direction to create a vortex flow of combustion gases through the annular combustion chamber. The flue gas is discharged through the center tube. In operation, a material to be dried and/or calcined is applied to the external wall of the rotatable drum as it rotates toward a scraper or doctor blade where the dried or calcined product is removed by scraping.
    Type: Grant
    Filed: May 1, 1998
    Date of Patent: May 25, 1999
    Assignee: Harper International Corp.
    Inventor: Jun Pei Zhou